Answer
Belumosudil mesilate (Rezurock) inhibits P-gp, OATP1B1 and BCRP, increasing plasma concentrations of substrates such as dabigatran or rosuvastatin, for which even minimal concentration changes may cause serious toxicity.
Sources for this answer
- REZUROCK 200 mg film-coated tablets.SANOFI · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked